secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0001789769-25-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuneOnco doses first patient in Instil's IMM2510 Phase 1b/2 NSCLC trial; data in 2H 2025
--------------------------------------------------------------------------------

- ImmuneOnco dosed first patient in combined-chemotherapy trial for advanced NSCLC in China.
- Initial clinical data for 1L advanced NSCLC expected as early as second half of 2025.
- Instil targets initiating U.S. first-line NSCLC trial of IMM2510 plus chemo in 2H 2025, subject to regulatory approvals.
- CEO Bronson Crouch says positive data could enable a global registrational study in front-line NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976925000003/0001789769-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976925000003/til-20250114.htm
  HTML page:      https://secwatch.observer/filing/0001789769-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer